Cannabis Formulation/Product Development Strategies for Medical/Recreational Oral Dosage Forms Recorded Webinar | Moe Harati | From: Jan 21, 2021 - To: Dec 31, 2021 |
Successful cannabis product development requires having the-end-in-mind regarding excipients-cannabinoids compatibility, shelf-life/product stability, and bioavailability of cannabinoids. This webinar will utilize the presenter’s expertise and experience in both the pharmaceutical and cannabis industries to provide guidance and examples of successful product development. You will learn various techniques to successfully initiate and optimize formulation for products containing cannabinoids.
Areas Covered in the Webinar:-
Why Should You Attend:-
The cannabis industry can learn from a well-established pharmaceutical to develop a successful product with an optimized formulation and subsequently longer shelf-life. This workshop will utilize the presenter’s 20+ years’ experience in leading various pharmaceutical and cannabis companies' research and development teams. The goal of this workshop is to provide participants with concepts, tips, and tricks of things to do and not to do for successful quick product development to either enter the recreational market or quick ANDA submission to FDA or other regulatory agencies.
We will explore the risk-based evaluation of product quality and the impact of excipients
Concept and application of quality by design including critical material attributes (CMA) and critical process parameters (CPP). Planning for excipient-cannabinoids compatibility will be explored in a generic format expandable to specific applications.
Various oral dosage forms will be reviewed including capsules, gummies, emulsions, and tables. Fill and shell formulation and compatibility for capsules will be explored by discussing various types of fill formulations.
The following questions will also be answered: What is the role of the excipient in a formulation? What is the relationship between Dissolution/disintegration and bioavailability of cannabinoids? What are different scenarios for the release of cannabinoids?
As part of this workshop, literature review, quality target product profile (QTPP) and concept of Quality Attributes (CQA) will be linked to proof-of-concept, i.e., bench work and comparable properties of the product such as dissolution and disintegration.
Who Will Benefit:-
From all industries, service and manufacturing companies working in cannabis and pharmaceuticals.
Dr. Harati is an expert and leader in pharmaceutical and cannabis industries with a broad research background and training in business administration that makes him able to quickly recognize challenges and provide clear, effective solutions. He has broad experience in research and development, product development, CMC product development, strategic planning and continuous improvement.
Dr. Harati is a high energy, tenacious leader that engages and inspires the team to own and execute the business plan with excellence. Over the past 20+ years, he has successfully led technical teams to develop novel products and analytical testing from discovery to commercialization. He facilitates fundamental product and process understanding and the advancement of innovative approaches to pharmaceuticals and cannabis development. Dr. Harati is author and presenter of more than 100 conferences, technical summaries, publications, funding white papers, and training guides.
